# SeNostic

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/senostic

- Industry: Biotechnology
- Headquarters: Braunschweig, Germany
- Website: www.senostic.com
- Latest round: Seed (Jan 25, 2016)
- Investors on record: 1

## About

SeNostic develops diagnostic solutions for neurodegenerative diseases, focusing on Alzheimer's and Parkinson's disease. Their innovative products enhance clinical trials and drug research, benefiting healthcare professionals and researchers globally.Founded in 2014 and headquartered in Braunschweig, Germany, SeNostic specializes in diagnostic solutions for neurodegenerative diseases. In January 2016, the company raised Seed funding from High-Tech Gründerfonds. It has conducted one deal to date, with its most recent activity being in early 2016.SeNostic specializes in the development of diagnostic solutions for neurodegenerative diseases, particularly focusing on conditions such as Alzheimer’s and Parkinson’s disease. The company's core offerings include in-vitro diagnostics (Dx) for clinical trials, recombinant proteins for research purposes, and tailored services aimed at drug research. These products are designed to enhance the understanding and treatment of neurodegenerative conditions, providing critical data that can facilitate more effective clinical interventions. The primary clientele includes pharmaceutical companies and research institutions involved in drug development, with a focus on markets across North America, Europe, and Asia. Through innovative research and product development, SeNostic aims to serve scientists and healthcare professionals devoted to advancing neurodegenerative disease therapies.SeNostic's revenue model is based on a combination of direct partnerships and B2B transactions with pharmaceutical companies and clinical research organizations. These transactions typically involve the provision of specialized diagnostic tools and recombinant proteins, which are integral to drug research and development processes. Clients engage with SeNostic through contractual agreements that outline specific service levels and product deliveries, ensuring tailored solutions that meet their research needs. The pricing structure for these services is designed to reflect the complexity and value of the diagnostic insights provided, with various plans available depending on the scope of research and number of services utilized. SeNostic’s flagship products, which are pivotal in drug trials and research, play a significant role in generating revenue through established long-term partnerships with key stakeholders in the pharmaceutical industry.SeNostic plans to leverage the funding raised in January 2016 to develop new diagnostic solutions aimed at enhancing research capabilities in neurodegenerative diseases. The company is targeting expansion into North American and Asian markets by 2025, intending to increase its product offerings and client base. Upcoming products are expected to be launched within the next 18 months, focusing on innovative diagnostics that cater to the evolving needs of the pharmaceutical sector.

## Funding rounds

- Seed, Jan 25, 2016 — High-Tech Gruenderfonds

## Investors

- High-Tech Gruenderfonds (https://capitalatlas.ai/funds/high-tech-gruenderfonds) — Seed